Why carry out this study?

In the RELIEVE-AD study, adult patients with moderate-to-severe atopic dermatitis reported that effectiveness of dupilumab was maintained during 1 year of follow-up.

Since longer-term data can inform the durability of this response from the perspective of patients in clinical practice settings, patients in the RELIEVE-AD study were recontacted 30–36 months after dupilumab initiation to determine if the treatment effects were maintained from the patient perspective.

What was learned from the study?

In this prospective, longitudinal, real-world study, patients reported maintenance of disease control and treatment satisfaction after 30–36 months of treatment, with a magnitude of improvement from baseline that was better than or comparable to the 12-month evaluation in all outcomes, including symptoms, flares, sleep problems, health-related quality of life, work/activity impairment, disease control, and treatment satisfaction.

Survey respondents reported long-term effectiveness of dupilumab for treatment of moderate-to-severe atopic dermatitis, with benefits observed after 12 months of therapy that were maintained up to 36 months.